Cidara Therapeutics Inc (CDTX) Return on Investment ROI from the third quarter of 2025 to third quarter of 2024 and for the year 2025, average high and low, overall ranking from Sep 30 2025 to Jun 30 2024 - CSIMarket
Cidara Therapeutics Inc's ROI from its third quarter of 2025 to the third quarter of 2024 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Cidara Therapeutics Inc's ROI in the third quarter of 2025?
Cidara Therapeutics Inc recorded a cumulative net loss of $-148 million during 12 months ending in the third quarter of 2025, resulting in a negative return on investment (ROI) of -48.15%.
Within the Healthcare sector 511 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the second quarter of 2025 from 3167 to 3829.
Cidara Therapeutics Advances with NAVIGATE Trial and Strategic Divestiture DecisionCidara Therapeutics, Inc. (Nasdaq: CDTX), a pioneering biotechnology company, has recently set significant milestones in its strategic trajectory, including the initiation of a Phase 2b clinical trial and the divestiture of one of its key assets. NAVIGATE Trial for Seasonal Influenza On April 24, 2024, Cidara Therapeutics announced the commencement of dosing in its Phase 2b NAVIGATE trial. The trial aims to evaluate CD388, a novel drug designed for the prevention of seasonal influenza. The extensive trial will enroll 5,000 subjects spread across various clinical sites in the United States and the United Kingdom. The primary of the NAVIGATE trial is to evaluate the safety and efficacy of CD388, potentially offering a groundbreaking therapeutic option for managing seasonal influenza.
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a leading biotechnology company based in San Diego, has recently announced a notable expansion of its Scientific Advisory Board (SAB) by appointing four distinguished experts in the field of infectious diseases: Rick Bright, Ph.D. Philip Krause, M.D. Mario Barro, Ph.D. and Frederick G. Hayden, M.D. FACP. This strategic move aims to bolster the company s capabilities as it strives to transition its innovative drug-Fc conjugate (DFC) immunotherapies from research to clinical application.The appointments come at a time when Cidara faces considerable financial headwinds. The company reported a cumulative net loss of $115 million in the twelve months ending in the second quarter of 2024, reflecting a staggering negative return on investment (ROI) of -308.87%. This stark figure places Cidara significantly behind competitors, with 506 other companies in the healthcare sector enjoying higher ROI. Despite this financial struggle, Cidara has made strides in improving its overall ranking, moving from 3504 in the first quarter of 2024 to 3043 by June 30, indicating a gradual recovery and strategic shift.
Cidara Therapeutics Restructures Workforce to Prioritize Clinical Development of CD388Cidara Therapeutics, Inc. (Nasdaq: CDTX), headquartered in San Diego, is a biotechnology company that has been gaining attention in the field of immunotherapies with its proprietary Cloudbreak® platform. The platform is designed to develop drug-Fc conjugate (DFC) immunotherapies tailored to save lives and improve patient outcomes for those battling serious diseases. Most recently, the company has made a significant decision to restructure its workforce in order to streamline its focus on the clinical development of its novel DFC candidate, CD388, targeting influenza A and B. This move impacts approximately 30% of the company s workforce and is intended to enhance its ability to bring this promising therapy to market. The Cloudbreak® Platform and CD388 The Cloudbreak® platform is a cornerstone of Cidara s innovative approach, enabling the creation of DFCs that combine the therapeutic potential of both the small molecule drugs and the targeting ability of antibodies. CD388, a noteworthy candidate emerging from this platform, is designed to tackle the significant health burden posed by influenza A and B viruses responsible for substantial morbidity and mortality globally.
Financial Statements
Cidara Therapeutics Inc's III. Quarter Investments
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
